BMS 741672
Alternative Names: BMS-741672Latest Information Update: 02 Oct 2021
At a glance
- Originator Bristol-Myers Squibb
- Class Analgesics; Antihyperglycaemics
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic neuropathies; Type 2 diabetes mellitus
Most Recent Events
- 10 Apr 2007 Preclinical trials in Inflammation in USA (unspecified route)